Antibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigen

BMC Biotechnology

Research Article

J Ignacio Casal¹  Rodrigo Barderas¹  Ingrid Babel¹  Alberto Peláez-García¹ 

[1] Functional Proteomics Laboratory. Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, 28040, Madrid, Spain;

关键词: scFv antibodies;    in vitro;    phage display;    antibody microarrays;   

DOI  :  10.1186/1472-6750-11-61

 received in 2010-12-10, accepted in 2011-06-02,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundAntibodies constitute a powerful tool to study protein function, protein localization and protein-protein interactions, as well as for diagnostic and therapeutic purposes. High-throughput antibody development requires faster methodologies with lower antigen consumption.ResultsHere, we describe a novel methodology to select human monoclonal recombinant antibodies by combining in vitro protein expression, phage display antibody libraries and antibody microarrays. The application of this combination of methodologies permitted us to generate human single-chain variable fragments (scFvs) against two proteins: green fluorescent protein (GFP) and thioredoxin (Trx) in a short time, using as low as 5 μg of purified protein. These scFvs showed specific reactivity against their respective targets and worked well by ELISA and western blot. The scFvs were able to recognise as low as 31 ng of protein of their respective targets by western blot.ConclusionThis work describes a novel and miniaturized methodology to obtain human monoclonal recombinant antibodies against any target in a shorter time than other methodologies using only 5 μg of protein. The protocol could be easily adapted to a high-throughput procedure for antibody production.

【 授权许可】

Unknown   
© Babel et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.